Policy support for disruptive innovation in the life sciences

Joyce Tait*, David Wield

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

This paper focuses on business models and value chains to analyse sectoral innovation systems involving synthetic biology and gene editing, as potentially disruptive platform technologies in the life sciences. In the context of industrial biotechnology, we propose that the extent to which an innovation is expected to be disruptive, and the location of that disruption in existing value chains, are relevant to policy decision making on how to govern innovative technologies. Policy decisions on how to regulate or support an innovative technology will be among the most important factors determining the extent to which it is able to deliver its disruptive potential, leading to sectoral transformations through new business models and value chains. This mode of thinking about disruption and innovation could be incorporated in standard procedures for policy makers to guide decisions designed to support translation from basic scientific research to societally useful products and processes.
Original languageEnglish
Pages (from-to)307-319
Number of pages13
JournalTechnology Analysis and Strategic Management
Issue number3
Early online date17 Jun 2019
Publication statusPublished - 2021

Keywords / Materials (for Non-textual outputs)

  • science & technology and innovation policy studies
  • foresight
  • radical/disruptive innovation
  • industrial biotechnolopgy


Dive into the research topics of 'Policy support for disruptive innovation in the life sciences'. Together they form a unique fingerprint.

Cite this